|Bid||6.55 x 1400|
|Ask||6.57 x 800|
|Day's Range||6.49 - 6.71|
|52 Week Range||2.01 - 6.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.42|
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain infectious diseases, announces that the United States Food and Drug Administration (“FDA”) inspection database classification website has been updated and confirms ADMA’s compliance status has improved to Voluntary Action Indicated (“VAI”). “We are pleased that the FDA has acknowledged the improved current good manufacturing practice (“cGMP”) conditions at our manufacturing facility and updated its database accordingly,” stated Adam Grossman, President and Chief Executive Officer of ADMA Biologics, Inc. “We are excited to finally be in a position to resubmit our Biologics License Application (“BLA”) for RI-002 during the third quarter of 2018, which we believe is a needed Intravenous Immune Globulin (“IVIG”) option for patients who suffer with Primary Humoral Immunodeficiency Disease (“PIDD”).
Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.
ADMA Biologics, Inc. (ADMA) filed its 10-K and press release for its second quarter 2018 financial results on August 10, 2018. The highlights year to date have included the release of the first commercial batch of Nabi-HB to be manufactured under ADMA ownership, the retirement of 8.6 million shares issued to Biotest and the grant of a patent for treating respiratory infections related to RI-002. On June 12, ADMA closed $40 million in equity financing followed just over six weeks later by the successful close out of the FDA compliance inspection.
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 27, 2018-- ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics ...
On a per-share basis, the Ramsey, New Jersey-based company said it had a loss of 35 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2018-- ADMA Biologics, Inc. today announced its financial results for the quarter ended June 30, 2018 and provided an update on its operations and corporate ...
ADMA Biologics, Inc. (ADMA) posted a press release announcing that the FDA had successfully closed out its April inspection of the Boca Raton BioManufacturing facility and announced the target action date for Bivigam’s prior approval supplement (PAS). The favorable outcome from the FDA inspection has been eagerly awaited as it is necessary for the company to resume production of Bivigam and refile the BLA for RI-002. The FDA communicated to management that the facility received “Voluntary Action Indicated” (VAI) status as a result of the inspection.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 26) ADMA Biologics Inc (NASDAQ: ADMA )(announced it has addressed ...
The EIR received by the Company contains detailed information about the April 2018 FDA inspection, discussions had with the investigators, requests for clarification and information, as well as a summary of potential next steps for the review of the Prior Approval Supplement (“PAS”) for BIVIGAM®. According to FDA guidance, when the Agency concludes that an inspection is “closed” under 21 CFR 20.64(d) (3), it releases a copy of the EIR to the inspected establishment. The EIR discusses many improvements and resolutions made by the Company to the majority of observations previously existing from the 2014 and 2016 FDA inspections of the Boca Raton, FL facility while owned and operated by Biotest Pharmaceuticals Corporation (“Biotest”). The Agency has requested specific clarification to certain historical inspectional deficiencies (from 2014 and 2016), some of which, the Company believes, will be addressed during the ongoing review of the PAS for BIVIGAM®. The EIR states that the FDA investigators were unable to review real time production of BIVIGAM® during the inspection and the report notes that the PAS had not yet been on file at the time of the April 2018 inspection.
Prior Approval Supplement to Amend the Biologics License Application for BIVIGAM ® is Supported by Data and Documentation Prepared Using ADMA’ s Optimized IVIG Manufacturing P rocess Demonstrating Robust ...
Russell indexes are widely used by institutional investors and index funds as benchmarks for active investment strategies. According to FTSE Russell, approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. A total of 211 companies will join the Russell 2000® Index during this year’s reconstitution.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 12) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
ADMA Biologics, Inc. (ADMA) filed its 10-K and press release for its first quarter 2018 financial results on May 14, 2018. The highlights year to date have included the release of the first commercial batch of Nabi-HB to be manufactured under its ownership, the retirement of 8.6 million shares issued to Biotest and the grant of a patent for treating respiratory infections related to RI-002. The facility has been inspection-ready by the turn of the year and we await the arrival of the FDA inspection team.
Today, I will be analyzing ADMA Biologics Inc’s (NASDAQ:ADMA) recent ownership structure, an important but not-so-popular subject among individual investors. A company’s ownership structure is often linked to its shareRead More...
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMA as the Company's latest news hit the wire. On May 16, 2018, the New Jersey-based biopharmaceutical Company announced that the United States Patent and Trademark Office has issued to ADMA US Patent No. 9,969,793 covering methods of treating respiratory infections. Active-Investors.com is currently working on the research report for Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), which also belongs to the Healthcare sector as the Company ADMA Biologics.
The Ramsey, New Jersey-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring costs, came to 35 cents per share. The infectious disease drug developer posted revenue ...
The most recent earnings announcement ADMA Biologics Inc’s (NASDAQ:ADMA) released in December 2017 revealed that losses became smaller relative to the prrior year’s level as a result of recent tailwindsRead More...